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BACKGROUND: This prospective pilot study determined the efficacy of previous transvaginal intraovarian 
injection with autologous platelet-rich plasma (PRP) in poor ovarian responders (PORs) fulfilling the Bologna 
criteria before in vitro fertilisation (IVF)/intracytoplasmic sperm injection (ICSI) with low dose ovarian stimulation. 
Current knowledge of efficient treatment for PORs is limited and often contradictory; also, LBRs of IVF remains 
disappointingly low. 
AIM: We assessed the live birth rates (LBRs) in PORs after previous ovarian treatment with PRP.  
METHODS: Overall, 40 patients undergoing IVF/ICSI between June 2017 ending December 2018 were included. 
A transvaginal intraovarian injection of PRP was performed on 20 patients. Both compered groups were balanced 
for all basic characteristics, and multivariate analysis was performed to adjust for all known confounders.  
RESULTS: Between the groups, a statistical significance in clinical pregnancies and LBR was not found. Clinical 
pregnancy and live birth rates were 33.33 ± 44.99 and 40.00 ± 50.71 in the PRP group and 10.71 ± 28.95 and 
14.29 ± 36.31 in control group retrospectively. However, there is a trend towards higher implantation rates and 
LBRs in patients with previous treatment with PRP. Anyhow, the number of patients used in the research is 
insufficient to make a concrete conclusion, and more studies are needed in the future to confirm these results 
entirely. 
CONCLUSION: Even though the treatment of POR responders remains as a therapeutical challenge, the usage 
of intraovarian injection of autologous PRP in PORs before the IVF performance brings a glimpse of new hope in 








The term poor ovarian responders (PORs) 
determines a subgroup of in-vitro patients who 
showcase a decreased response to classical ovary 
stimulation with gonadotropins, usually as a result of 
decreased ovary reserves. The IVF procedure results 
in a decreased number of received oocytes, a 
decreased clinical pregnancy and LBR [1]. The latest 
meta-analysis performed by the American Society for 
Reproductive Medicine (ASRM) in regards to the 
efficiency of different protocols of ovary stimulation 
demonstrates an increased cost-benefit with the 
usage of low dose stimulation using GnRH 
antagonists [2]. When taking into consideration the 
need for donating egg cells and different ethical and 
religious questions that impose themselves, it’s clear 
that there’s a need for an additional alternative option 
that will solve these issues. Therefore, the use of 
platelet-rich plasma (PRP) is considered as a justified 
and potentially successful opportunity with which the 
fertility outcome in PORs may be increased [3], [4]. 
PRP, as a method in many medical fields, has 
already demonstrated its beneficial effect on tissue 
regeneration, angiogenesis activation, inflammation 
control and anabolism [5]. Unfortunately, there are still 
insufficient clinical data in the field of ovarian infertility. 
PRP has been used for the first time as a medical 
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term in 2007 as: “a preparation consisting of 
concentrated platelets in a limited plasma volume. It is 
used in various regeneration procedures of surgical 
tissues, where growth factors from platelets can affect 
the speeding up of healing and regeneration of the 
wounds” [6]. Platelets are cytoplasmic fragments of 
megakaryocytes, which are formed from the bone 
marrow and are approximately 2 µm in diameter [7]. 
Activating the alfa granules from the platelets is one of 
the most crucial steps which affects the availability of 
released bioactive molecules, and Ergo, the quality of 
the PRP. Namely, they contain more than 800 
proteins, such as cytokines, hormones, and chemo-
attractants of stem cells, macrophages, and 
neutrophils; these molecules have a fundamental role 
in the hemostasis and the tissue regeneration [8]. 
The method of receiving PRP is simple, 
minimally invasive and at a low cost. The high 
concentration of factors of growth and cytokines 
present in the PRP affects the balance between the 
anabolic and katabolic process, optimising the tissue’s 




Material and Methods 
 
Patient selection 
In this pilot study, 40 patients were included. 
A written consent form was received by all patients. 
Also, all patients were completely informed regarding 
the case study and the way of stimulation during our 
research. Patients were divided into two groups, 
group A and B. The group A consisted of 20 patients, 
who received a transvaginal intraovarian injection of 
autologous platelet-rich plasma, before the 
commencement of an IVF. The choice of this 
treatment was made after a clear and thorough 
discussion with the patient/couple. In both groups, 
there wasn’t a statistically significant difference in 
regards to age, BMI, hormonal status, number of 
antral follicles, previous IVF attempts and duration of 
infertility. Both compered groups were balanced for all 
basic characteristics, and multivariate analysis was 
performed to adjust for all known confounders. The 
timeframe between the application of PRP until ovary 
stimulation for IVF was 61 ± 18 days. 
The study was approved by the local Ethics 
Committee, and the Institutional Review Board and 
each patient included in the study signed an informed 
written consent. The study included PORs who meet 
at least two of the following three Bologna criteria, 
published by the European Society of Human 
Reproduction and Embryology (ESHRE) in 2011 [10]. 
Only women whose partners’ have normal semen 
analyses were reviewed [11]. It is important to note 
that only patients where the IVF process was 
completed with an embryo transfer were included in 
the study. The exclusion criteria were ovarian 
insufficiency due to gonadal dysgenesis and 
chromosomal abnormalities, immunoglobulin A 
deficiency, large surgical repairs of pelvic floor leading 
to the creation of severe pelvic adhesions, the use of 
anticoagulants, psychotropic medicaments, 
psychiatric disorders, carcinomas or a history of 
chronic pelvic pain [12]. Women with present 
infection, haemoglobin lower than 11 g/L or platelets 
lower than 150 x 10
ᶾ
/µL were excluded from the study. 
Patients who participated in the study were aged from 
35 to 42. 
 
Sample preparation 
According to the classification proposed by 
Ehrenfest, 4 different types of PRP are defined, 
depending on the content of cells and the presence of 
fibrin [13]. In regards to the Classification of PRP in 
this case study, it is used as a commercial type of 
PRP with the lower concentration (2.5 x 3 times) 
system, Regen PRP, (Regen Laboratory, Mont-sur-
Lausanne, Switzerland) [14]. The process was carried 
out under strict aseptic conditions as well as optimum 
temperature regulations, i.e., 21-24°C. PRP was 
prepared according to the manufacturer’s guidelines. 
In the last step, the volume immediately above the 
erythrocyte layer was collected. Calcium gluconate 
was used as an activator. After activation, in a period 
less than 2 min, approximately 3-5 ml of the PRP was 
injected into the ovaries under transvaginal ultrasound 
guidance. The intervention was made under propofol 
intravenous anaesthesia following a protocol set by 
our IVF department. The whole intervention lasted 
about 15 to 20 minutes. We used a 30 cm single 
lumen 17G aspiration needles (COOK/Australia) 
The changes in hormones FSH, estradiol, 
AMH was closely monitored, both before and after the 
application of PRP. We observed changes in the 
number of antral follicles before and after the 
application of PRP. In both groups, we used the same 
protocol for ovary stimulation, a low dose stimulation 
using GnRH antagonists. 
 
Stimulation protocols and IVF procedure 
The ovarian stimulation was performed 
according to the recommendations of the Practice 
Committee of the American Society for Reproductive 
Medicine [2]. A mild ovarian-stimulation protocol was 
performed in all patients. The protocol used 100-
mg/day clomiphene citrate on days 2-6 of the cycle, 
adding the low-dose human menopausal 
gonadotropin (≤ 150 IU/d) and an antagonist 
(Cetrotide 0.25) when a lead follicle was ≥ 14 mm. 
During the controlled ovarian stimulation, we followed 
a protocol set by our IVF department. We evaluated 
several parameters such as estradiol (E₂), number 
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gonadotropins administration with ultrasonography 
and laboratory tests. When one or more leading 
follicles reached a mean diameter ≥ 18 mm and the 
estradiol level was ≥ 200 pg/ml, human chorionic 
gonadotropin (hCG, 5 000 IU; Pregnyl, N.V. Organon, 
Os, The Netherlands) was administered for triggering 
the maturation of oocytes. Administration of FSH 
continued up until the application of HCG. 
Transvaginal ultrasound-guided oocyte retrieval was 
performed under short intravenous anaesthesia 
(Propofol-Lipuro 1%, Braun Melsungen AG, 
Melsungen, Germany). In both subgroups, 
transvaginal ovary punctuation followed after 35 to 36 
hours of the application of HCG. The ICSI technique 
was used for all research patients. Embryo-transfers 
were applied 3 to 5 days later, depending on the 
condition and the work schedule of the IVF 
department. The same was performed under 
ultrasound control. Semen analysis was performed 30 
min following liquefaction followed by semen sample 
preparation by density gradient centrifugation using 
90% and 50% PureCeption (SAGE, Trumbull, CT, 
USA). Embryos were classified according to the 
scoring system of Hardarson and colleagues [15]. All 
transfers were performed under abdominal 
ultrasonography guidance using an embryo catheter 
(K-SOFT 5000, Cook Medical, Eight Mile Plains, 
Brisbane, Australia). Intravaginal administered 
progesterone (Crinone 8%, Merck Serono, Darmstadt, 
Germany) was used as the luteal phase support. The 
pregnancy test was considered positive when positive 
serum hCG levels (> 30 IU/ml) was detected 14 days 
after embryo transfer (ET). Clinical pregnancy was 
considered established when at least one visible sac 




Data analysis is performed in a Statistic 
program 7.1 for Windows and SPSS Statistics 23.0. 
For normal distributed data, mean and standard 
deviation were used. Comparisons across means 
were evaluated by paired two-tailed Students t-test. 
The factors with a P-value of < 0.1 in the univariate 
analysis were included in the logistic model. A P-value 





Mean patient's age was in the group A 37.47 
± 3.87 years, BMI was 22.63 ± 3.81 kg/m²; infertility 
duration was 4.0 ± 2.1 year. The mean partner age 
was 42.40 ± 5.34 years. All patients had multiple 
previous IVF attempts. Most of the patients had 
previous diagnostic hysteroscopy and laparoscopy. 
Differences in serum concentration of FSH, estradiol, 
AMH and total AFC in both groups were demonstrated 
in Table 1. Both compered groups were balanced for 
all basic characteristics, and multivariate analysis was 
performed to adjust for all known confounders. 
Between the two groups, there wasn’t a statistical 
significance found in regards to the age, BMI, the 
basal value of FSH and AMH, length of infertility, 
previous attempts of IVF. The mean value of platelet 
concentration was 226.27 ± 82.80/10⁹L. Further 
analysis was performed to identify factors that might 
correlate the platelet count in the PRP with the values 
of FSH, AMH, estradiol and total AFC post-PRP. 
None of the tests presented statistical significance. 
Table 1: Baseline characteristics of patients in both groups 
Characteristics 
Group A with previous treatment 
With autologous platelet-rich plasma Group B P 
Age 37.47 ± 3.87 37.64 ± 3.20 P = 0.99 
Body mass index kg/m² 22.63 ± 3.81 24.07 ± 5.01 P = 0.42 
Infertility duration 4.0 ± 2.1 4.5 ± 1.2 P = 0.37 
Partners age 42.40 ± 5.34 41.26 ± 4.38 P = 0.83 
FSH 19.27 ± 2.29 19.22 ± 4.05 P = 0.97 
Estradiol on day 3 71.06 ± 31.30 72.54 ± 28.64 P = 0.85 
AMH 0.35 ± 0.19 0.72 ± 0.42 P = 0.03 
E2, estradiol; FSH, follicle-stimulating hormone; AMH, anti-Müllerian hormone; antral 
follicle count; p Values pre- vs post-PRP calculated by Students t-test. 
 
Ovarian stimulation parameters such a mean 
total gonadotropin dose consumed during IVF, mean 
serum estradiol before HCG trigger, the number of M 
II oocytes obtained in patients and duration of 
stimulation are demonstrated in Table 2. 
Table 2: Compered ovarian stimulation parameters between 
groups 
Characteristics 
Group A with previous treatment 
with autologous platelet-rich 
plasma 
Group B P 
Number of ampules 75IE 38 ± 13.9 42 ± 12.91 P = 0.08 
Estradiol on day of HCG pmol/L 444.53 ± 331.87 528 ± 315.99 P = 0.57 
Number of oocytes 1.87 ± 1.13 3.71 ± 2.40 P = 0.20 
Duration of stimulation 10 (9.8-10.2) 10.2 (10-10.4) P = 0.92 
*Data presented as Breakdown & one-way ANOVA. 
 
ICSI was used in all cases. All results were 
made based on IVF/. ET cycle. For all patient’s fresh 
embryo transfers were performed. None of the 
patients experienced any complications from 
controlled ovarian stimulation or oocyte retrieval.  
Our results of IVF outcome group A such a 
fertilisation rate 80.67 ± 25.42, implantation rate 33.33 
± 44.99, clinical pregnancy rate 33.33 ± 44.99 and live 
birth rate 40.00 ± 50.71 and in group B 65.60 ± 25.35, 
10.71 ± 28.95, 10.71 ± 28.95, 14.29 ± 36.31 
retrospectively were demonstrated in Table 3. 
Table 3: Compared parameters of IVF treatment outcomes 
between groups 
Characteristics 
Group A with previous treatment 
with autologous platelet-rich plasma Group B P 
Fertilization rate 80.67 ± 25.42 65.60 ± 25.35 P = 0.44 
Implantation rate 33.33 ± 44.99 10.71 ± 28.95 P = 0.70 
Clinical pregnancy rate 33.33 ± 44.99 10.71 ± 28.95 P = 0.69 
    
Live birth rate 40.00 ± 50.71 14.29 ± 36.31 P = 0.71 
*Data presented as Breakdown & one-way ANOVA. 
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In this study, we can track a tendency of 
increasing the rate of clinical pregnancy and the live 
birth rates in Bologna poor responders, after the 
usage of the PRP method before the commencement 
of ovary stimulation during the IVF process. 
Currently, there isn’t a published randomised 
controlled study, which researched the effect of 
intraovarian injection of autologous PRP in poor 
responders. Available studies by the pioneer of PRP, 
professor Pantos and Sills [3], [4], showcasing the 
efficiency of using PRP on a larger indication scale. 
The way PRP affects the patient is still not 
completely evaluated. With the use of platelet-derived 
growth factors (PDGFs), dysfunctional ovarian tissue 
is believed to be supplied with essential factors 
necessary for ovarian regeneration. In this context, it 
is necessary to mention angiogenesis and follicular 
vascularisation and their significant role in the ageing 
of the follicles. Receptors for growth factors are 
present on granulose cells confirming their association 
with the activation process of the primordial follicles 
[16]. Confirmation of all the above statements is also 
obtained from the Hosseini study [17]. On the other 
hand, the presence of ovarian stem cells on the 
surface of the ovarian tissue, under certain conditions, 
can produce de novo primordial follicles and thus the 
appearance of new antral follicles [18]. For this 
reason, it is considered that it can also be a result of 
the possibility of stimulation of germinative cells from 
the ovary cortex [19]. 
Besides, it is also not completely clear the 
exact reason to which we attribute the trend to 
increasing LBRs compared to the group b where a 
PRP was not performed before performing an IVF. Is 
it an improvement on the number of egg cells and/or 
their quality? 
Anyhow, it is generally accepted that these 
patients need to be presented with all possible 
alternative treatments for a successful IVF with their 
genetic material. With a special emphasis on patients 
who fulfil the Bologna Criteria for POR and for patients 
who do not wish to enter a program for donating egg 
cells. 
In conclusion, even though the treatment of 
POR responders remains as a therapeutical 
challenge, the usage of intraovarian injection of 
autologous PRP in PORs before the IVF performance 
brings a glimpse of new hope in increasing the 
success of IVF defined by clinical pregnancy and 
LBRs. 
The conclusion in this study has to be 
reviewed extremely carefully because of the small 
number of patient participants in this pilot research 
study. For us to make a conclusion that would have 
significant statistical value, we would need a larger 
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